Document is current
Any future updates will be listed below
-
Authors
Sopp, Joshua M. http://orcid.org/0000-0002-4575-2156
Peters, Shirley J.
Rowley, Tania F.
Oldham, Robert J. http://orcid.org/0000-0002-8007-1145
James, Sonya
Mockridge, Ian
French, Ruth R.
Turner, Alison
Beers, Stephen A. http://orcid.org/0000-0002-3765-3342
Humphreys, David P.
Cragg, Mark S. http://orcid.org/0000-0003-2077-089X
-
Funding
Funding for this research was provided by:
Cancer Research UK (A24721)
RCUK | Biotechnology and Biological Sciences Research Council (BB/N5039927/1)
- License Information
-
More Information
Article History
Received: 23 September 2020
Accepted: 2 August 2021
First Online: 2 September 2021
Competing interests
: The authors declare the following competing interests: M.S.C. is a retained consultant for BioInvent International and has performed educational and advisory roles for Roche, Boehringer Ingelheim, Baxalta, Merck KGaA and GLG. He has received research funding from Bioinvent, Roche, Gilead, iTeos, UCB and GSK. T.F.R., S.J.P. and D.P.H. are employees of UCB. The remaining authors declare no competing interests.
